These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20554570)

  • 1. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.
    Crompton JA; North DS; Yoon M; Steenbergen JN; Lamp KC; Forrest GN
    J Antimicrob Chemother; 2010 Aug; 65(8):1784-91. PubMed ID: 20554570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections.
    Jobson S; Moise PA; Eskandarian R
    Clin Ther; 2011 Oct; 33(10):1391-9. PubMed ID: 22015328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
    Ruiz J; Ramirez P; Concha P; Salavert-Lletí M; Villarreal E; Gordon M; Frasquet J; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Sep; 14():141-144. PubMed ID: 29601996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
    Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
    Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
    Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the minimum inhibitory concentration of daptomycin on the outcomes of Staphylococcus aureus bacteraemia.
    AlQahtani H; Baloch S; Aleanizy FS; Alqahtani FY; Tabb D
    J Glob Antimicrob Resist; 2021 Mar; 24():23-26. PubMed ID: 33279686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?
    Ruiz-Ramos J; Vidal-Cortés P; Díaz-Lamas A; Reig-Valero R; Roche-Campo F; Del Valle-Ortiz M; Nuvials-Casals X; Ortiz-Piquer M; Andaluz-Ojeda D; Tamayo-Lomas L; Blasco-Navalpotro MA; Rodriguez-Aguirregabiria M; Aguado J; Ramirez P
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1569-1575. PubMed ID: 28378244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.
    McDaneld PM; Spooner LM; Mohr JF; Belliveau PP
    Ann Pharmacother; 2013 Dec; 47(12):1654-65. PubMed ID: 24259618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM; Rojtman AD
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
    Appleman MD; Citron DM
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
    Sader HS; Becker HK; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
    Lalani T; Boucher HW; Cosgrove SE; Fowler VG; Kanafani ZA; Vigliani GA; Campion M; Abrutyn E; Levine DP; Price CS; Rehm SJ; Corey GR; Karchmer AW;
    J Antimicrob Chemother; 2008 Jan; 61(1):177-82. PubMed ID: 17999973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus.
    San-Juan R; Viedma E; Chaves F; Lalueza A; Fortún J; Loza E; Pujol M; Ardanuy C; Morales I; de Cueto M; Resino-Foz E; Morales-Cartagena A; Rico A; Romero MP; Orellana MÁ; López-Medrano F; Fernández-Ruiz M; Aguado JM
    Emerg Infect Dis; 2016 Jun; 22(6):1057-66. PubMed ID: 27192097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.